NCT01518413 - Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Rhabdomyosarcoma and Other Soft Tissue SarcomasEwing's Sarcoma Family of TumorsOsteosarcomaNeuroblastomaBrain Tumors

Interventions

DRUG

sorafenib

sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.

DRUG

irinotecan

irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days

Trial Locations (4)

The Children's Hospital of Philadelphia, Philadelphia

Children's National Medical Center, Washington D.C.

National Cancer Institute, Bethesda

Children's Hospital Boston/Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

HMeany

OTHER